ELAVL1 and prostate carcinoma: The introduction of a miR-34a precursor into paclitaxel and hormone-resistant prostate cancer cells caused a decrease of HuR, bcl-2, and SIRT1 expression and inhibition of the SIRT1 3′UTR activity.